Changes Requested for Testosterone Therapy Labels

The US Department of Health and Human Services has requested updates to testosterone replacement therapy labels for men, based on new safety data and findings. This could potentially make access to testosterone therapy easier for those who need it.

One of the key changes includes removing a previous warning that stated the safety and effectiveness of testosterone therapy weren’t established for men with age-related low testosterone. This was announced by HHS on Thursday.

Additionally, the agency suggests updates regarding the risk of prostate cancer and alterations to warnings about enlarged prostate conditions.

“By improving the information on testosterone therapy labels, we aim to provide clearer guidance to both patients and physicians. This supports informed medical decisions and better healthcare for many American men,” said HHS Secretary Robert F. Kennedy Jr.

Experts caution, however, that patients should still have comprehensive discussions with their doctors about the suitability of testosterone therapy for their specific cases, which is essential for proper evaluation.

Though the announcement marks a step forward, Dr. Jamin Brahmbhatt, a urologist and men’s health expert, pointed out that no official changes have been made to the labels yet. He noted that just because a warning might be removed doesn’t imply that every man should be prescribed testosterone therapy.

“It’s important to remember that testosterone is still a medical therapy, not merely a wellness treatment,” he said. “The proposal should not lead to unrestricted prescribing; guidelines are still necessary for any medical therapy. I hope these clearer labels will encourage insurers to cover it for those who truly require it.”

Concerns about testosterone therapy have included risks like heart issues, prostate cancer, and accelerated growth of prostate tissue, all of which have influenced how therapies are labeled and administered.

In 2015, the FDA mandated changes indicating that the safety and effectiveness of testosterone therapy hadn’t been proven for men with low testosterone due to idiopathic hypogonadism, mainly due to limited evidence of benefits and concerns about cardiovascular risks.

Since then, research has indicated that there’s no significant increase in major cardiovascular events such as heart attack or stroke for those receiving testosterone therapy, according to HHS.

Furthermore, the understanding of prostate cancer risks related to testosterone therapy has evolved. Current labels generally advise against its use in men with known or suspected prostate cancer. However, emerging data suggests there might not be an increased risk associated with testosterone therapy, as the updated guidelines would limit this warning mainly to men whose cancer has metastasized.

As for warnings about benign enlarged prostate, current labels caution that testosterone may aggravate these symptoms. However, recent FDA reviews have found insufficient evidence of this in men with mild to moderate symptoms. For those with severe symptoms, HHS suggests continued monitoring during treatment.

Dr. Eddie Hackler III, a cardiologist, expressed that the new request could help alleviate some fears regarding testosterone therapy. “There are proven advantages for specific symptoms—like improved libido and mood—but proper diagnosis is vital before beginning therapy,” he stated.

He also mentioned that current trial data don’t suggest an elevated risk of heart attacks or strokes associated with testosterone therapy. However, potential side effects may still include skin reactions, acne, and others, which should be considered.

This latest move by HHS follows the Trump administration’s broader aim to lift restrictions on hormone therapies. Last year, similar efforts were made regarding hormone therapy for women, where “black box” warnings were removed from certain products.

In December, the FDA conducted discussions on testosterone replacement therapy for men and has been exploring new treatment options since then.

Dr. Adam Baumgarten from the University of Alabama at Birmingham described the label changes as overdue. He pointed out that the concerns around cardiovascular safety linked to testosterone therapy have not been supported by recent trial data. He emphasized that the FDA’s prostate cancer warnings have become more nuanced, focusing largely on men with advanced cancer and reiterating the need for clear diagnoses and ongoing monitoring during therapy.

Overall, testosterone levels considered low in adults are typically below 300 nanograms per deciliter, but normal levels can vary widely. Baumgarten highlighted that it’s important to confirm low testosterone levels through repeated tests alongside symptoms like fatigue or low sex drive.

While the benefits for genuinely low testosterone can be significant, there are valid concerns regarding its use among men whose levels fall within normal ranges but seek improvement for wellness reasons, according to Brahmbhatt. He cautioned against making unwarranted health decisions based on trends and influencers, as testosterone can have notable side effects.